Velsipity
(Etrasimod)ApprovedSmall molecule
PfizerEtrasimod is used to treat ulcerative colitis, an inflammatory bowel disease that causes inflammation and ulcers in the colon. It helps reduce symptoms like diarrhea, abdominal pain, and rectal bleeding by calming the immune system in the gut.[2] Velsipity is currently approved and in use across 5 indications[4].[1]
Velsipity is one of 60 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.
5
Indications
28
Total Trials
11
Active Trials
59
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
104 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Velsipity
PfizerApproved
Humira
NovartisPhase 3
Stelara
Johnson & JohnsonPhase 3
Jyseleca
GileadPhase 3
Skyrizi
AbbViePhase 3
Tremfya
Johnson & JohnsonPhase 3
Mounjaro
Eli LillyPhase 3
Mesalazine
FerringPhase 3
Plaquenil
Jazz PharmaceuticalsPhase 2
Jardiance
Boehringer IngelheimPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis10 trials
Show 7 more trials
Colitis, Ulcerative3 trials
Atopic Dermatitis2 trials
Medication2 trials
9 more indications
Breastfeeding1 trial
Eosinophilic Esophagitis1 trial
Alopecia Areata1 trial
ESS1 trial
Etrasimod1 trial
Regulatory
FDA Approval Timeline[5]
Jun 5, 2024
VELSIPITY
NDA NDA216956
Aug 12, 2025
VELSIPITY
NDA NDA216956
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Velsipity drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Etrasimod. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]